PDCD1 rs2227981: Understanding This Genetic Variant and Cancer Risk
The rs2227981 variant is a single nucleotide polymorphism located within the PDCD1 gene, which encodes the PD-1 protein. Research has investigated its potential association with susceptibility to various cancers, though findings remain inconsistent across different populations and tumor types.
What each genotype means
Baseline cancer risk profile
This is the most common genotype for this variant. Some research suggests that individuals with this genotype may have a different susceptibility to certain cancers compared to those with the T allele, though findings are inconsistent across different populations and cancer types. This variant is a synonymous change, meaning it does not alter the protein structure of PD-1.
This is the most frequently observed genotype in many studied populations, such as in a Turkish cohort where it was found in approximately 44% of individuals.
Variable cancer risk profile
Carriers of this genotype have one copy of the T allele. Some studies have observed that this genotype may be associated with altered cancer risk in specific contexts, such as digestive system tumors, while other research suggests it may have a protective effect in different populations. Because the evidence is mixed and highly dependent on ancestry and cancer type, this result should not be used to predict individual health outcomes.
This genotype is common, appearing in approximately 42% of individuals in some reported cohorts.
Potential reduced cancer susceptibility
Some meta-analyses have associated the TT genotype with a statistically decreased risk for certain types of cancer compared to the CC genotype. However, these findings are not universal and vary significantly by ethnicity and the specific type of malignancy being studied. This variant is located in the PDCD1 gene, which plays a role in immune regulation, but the clinical significance of this specific genotype remains limited.
This is the least common genotype for this variant, observed in approximately 14% of individuals in some studied populations.
What is rs2227981?
The variant rs2227981 is a single nucleotide polymorphism (SNP) found in the PDCD1 gene. In genetic literature, it is sometimes referred to as PD-1.5. A SNP represents a variation at a single position in the DNA sequence among individuals. In the case of rs2227981, the variation involves a change between the C and T alleles. This variant is located in a region of the gene that may influence how the PD-1 protein is expressed or regulated. Because it is a non-coding variant, it does not change the amino acid sequence of the protein itself, but it may affect the efficiency or timing of gene expression. Scientists study such variants to understand how subtle differences in our genetic code might contribute to individual differences in immune system function and disease susceptibility.
The Role of the PDCD1 Gene
The PDCD1 gene provides instructions for making the Programmed Cell Death-1 (PD-1) protein. This protein is primarily found on the surface of T cells, which are specialized immune cells that help protect the body from infections and abnormal cells, including cancer. PD-1 acts as an 'immune checkpoint,' functioning like a brake to prevent the immune system from becoming overactive and attacking the body's own healthy tissues. While this mechanism is essential for preventing autoimmunity, cancer cells can sometimes exploit this pathway to 'turn off' T cells, allowing the tumor to evade immune detection. Because of this, the PD-1 pathway has become a major target for cancer immunotherapies, which aim to release these brakes and allow the immune system to recognize and destroy cancer cells more effectively.
Research Associations and Evidence Strength
The association between rs2227981 and cancer risk is a subject of ongoing scientific debate. Several meta-analyses have suggested that this variant may be linked to a decreased risk of certain cancers, while other studies have reported conflicting results or found associations with increased risk for specific types, such as female-specific hormone-dependent cancers. The evidence is considered limited and often inconsistent, as results frequently vary depending on the population studied, the specific type of cancer, and the methodology used. For instance, some studies have observed significant associations in East Asian cohorts that were not replicated in other populations. Because these findings are based on observational case-control studies rather than clinical trials, they demonstrate statistical correlations rather than direct causation. The complexity of cancer development means that genetic variants like rs2227981 likely interact with many other environmental and genetic factors.
What You Can and Cannot Do With This Information
It is important to understand that having a specific genotype for rs2227981 does not mean an individual will or will not develop cancer. Genetic predisposition is only one small piece of a much larger puzzle that includes lifestyle, environment, and other genetic factors. This information is intended for educational purposes and should not be used for medical diagnosis or to predict personal health outcomes. If you are concerned about your cancer risk, the most effective steps involve consulting with a healthcare professional regarding established screening guidelines and healthy lifestyle choices. Never make changes to your medical care or treatment plans based on genetic data without first discussing them with your doctor or a qualified genetic counselor. They can provide context based on your personal and family medical history, which is far more predictive than any single genetic variant.
How common is this variant?
The frequency of the C and T alleles for rs2227981 varies significantly across different global populations, though specific comprehensive frequency data is not uniformly recorded in all major databases.
Frequently asked questions
Does rs2227981 mean I will get cancer?
No. Genetic variants like rs2227981 are associated with statistical trends in large populations, not individual outcomes. Cancer is a complex disease influenced by many factors, and this variant is not a diagnostic tool.
Should I get tested for this variant?
There is no clinical recommendation to test for this variant. It is currently a subject of research, and the results do not provide actionable information for personal medical management.
How does PD-1 affect cancer treatment?
PD-1 is a target for immunotherapy drugs known as checkpoint inhibitors. These treatments help the immune system recognize and attack cancer cells, but their effectiveness depends on many factors beyond a single genetic variant.
Where can I find more information on PDCD1?
You can explore resources like MedlinePlus Genetics or the National Center for Biotechnology Information (NCBI) for general information on genes and their functions. Always consult a doctor for questions about your specific health.
Sources & further reading
Educational information only, last refreshed 10/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2227981?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29